6 completed, 2 terminated, 2 withdrawn, 1 no longer available. 7 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Withdrawn 2, Terminated 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow CytRx: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer Tamibarotene, Placebo - Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion, Stage IV Non-small Cell Lung Cancer | Phase 2 | Terminated | CytRx | 140 | 2011-04-01 | 2013-06-28 |
| Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer Bafetinib - Hormone Refractory Prostate Cancer | Phase 2 | Completed | CytRx | 23 | 2010-08-01 | 2011-12-15 |
| Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) bafetinib - B-Cell Chronic Lymphocytic Leukemia | Phase 2 | Completed | CytRx | 20 | 2010-06-01 | 2013-05-15 |
| Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Tamibarotene, Arsenic trioxide - Acute Promyelocytic Leukemia | Phase 1 | Terminated | Northwestern University | 4 | 2009-10-01 | 2013-10-30 |
| INNO-206 in Patients With Small Cell Lung Cancer (SCLC) INNO-206 - Small Cell Lung Cancer | Phase 2 | Withdrawn | CytRx | 2008-05-01 | 2012-02-09 | |
| Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL Tamibarotene - Acute Promyelocytic Leukemia | Phase 2 | Completed | CytRx | 15 | 2007-09-01 | 2013-02-13 |
| Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia INNO-406 - Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 1 | Completed | CytRx | 100 | 2006-07-01 | 2009-06-01 |
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS arimoclomol - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Completed | CytRx | 80 | 2005-10-01 | 2012-02-09 |
| Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease poloxamer 188 - Sickle Cell Anemia | Phase 3 | Completed | Mast Therapeutics, Inc. | 300 | 1997-11-01 | 2012-03-06 |
| A Multicenter, Double-Blind Study to Investigate the Safety and Efficacy of Arimoclomol in Volunteers With ALS Placebo, Arimoclomol - Amyotrophic Lateral Sclerosis | Phase 2 | Withdrawn | CytRx | 2012-02-09 | ||
| Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy aldoxorubicin - Sarcoma | No longer available | CytRx | 2015-10-22 |
Amyotrophic Lateral Sclerosis (2) · Leukemia, Promyelocytic, Acute (2) · Anemia, Sickle Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Pain (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Rare Diseases (1) · Sarcoma (1) · Small Cell Lung Carcinoma (1)
bafetinib (3) · tamibarotene (3) · DOXO-EMCH (2) · arimoclomol (2) · Arsenic Trioxide (1) · Poloxamer (1)
United States (10) · Bulgaria (1) · Canada (1) · Germany (1) · India (1) · Israel (1) · Mexico (1) · Russia (1) · Ukraine (1)
Daniel Levitt, M.D., Ph.D. (2) · Hagop Kantarjian, M.D. (1) · Jeremy Shefner, MD (1) · Jeremy Shefner, MD, PhD (1) · Jorge Cortes, MD (1) · Merit Cudkowicz, MD (1) · Merit Cudkowicz, MD, MSc (1) · Michael Maitland, MD (1) · Oscar Arrieta, M.D. (1) · R. Martin Emanuele (1)